PhotoPharmics Enrolls First 100 Participants in Groundbreaking Parkinson's Disease Trial

SALT LAKE CITY--(BUSINESS WIRE)-- #medicaldevices--PhotoPharmics, a leader in neurodegenerative disease phototherapy, today announced the enrollment of the first 100 subjects in its Light for PD clinical trial. This marks a significant milestone in evaluating Celeste, the company’s FDA Breakthrough light therapy device for Parkinson's disease (PD). Organizers are on track to enroll 300 subjects—interested individuals with PD may find details at lightforpd.com. The Light for PD trial is a randomized, double-blind